Joanne Cono
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joanne Cono has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Denise J. Jamieson
Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, GA
2 shared publications Janet D. Cragan
Centers for Disease Control and Prevention, Atlanta, Georgia, USA
2 shared publications- Sonja A. Rasmussen
Department of Genetic Medicine and Department of Gynecology and Obstetrics, Johns Hopkins School of Medicine, Baltimore, Maryland (S.A.R.).
2 shared publications Harold Jaffe
Joanne Cono is the Director of the Office of Science Quality, Office of the Associate Director for Science, and Harold Jaffe is the Associate Director for Science, Centers for Disease Control and Prevention, Atlanta, GA
1 shared publication
Latest Publications
- 1 June 2015
- Published by American Public Health Association in American Journal of Public Health
- Vol. 105 (6) , e1-e2
The CDC Clearance Process: Supporting Quality Science
- 1 June 2015
- Published by American Public Health Association in American Journal of Public Health
- Vol. 105 (6) , e1-e2
The CDC Clearance Process: Supporting Quality Science
- Open Access
- 1 March 2007
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 13 (3) , 518-519
Pregnancy and Emerging Diseases
- 1 March 2007
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 13 (3) , 518-519
Open AccessPregnancy and Emerging Diseases
- Open Access
- 1 November 2006
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 12 (11) , 1631-1637
Prophylaxis and Treatment of Pregnant Women for Emerging Infections and Bioterrorism Emergencies
Emerging infectious disease outbreaks and bioterrorism attacks warrant urgent public health and medical responses. Response plans for these events may include use of medications and vaccines for which the effects on pregnant women and fetuses are unknown. Healthcare providers must be able to discuss the benefits and risks of these interventions with their pregnant patients. Recent experiences with outbreaks of severe acute respiratory syndrome, monkeypox, and anthrax, as well as response planning for bioterrorism and pandemic influenza, illustrate the challenges of making recommendations about treatment and prophylaxis for pregnant women. Understanding the physiology of pregnancy, the factors that influence the teratogenic potential of medications and vaccines, and the infection control measures that may stop an outbreak will aid planners in making recommendations for care of pregnant women during large-scale infectious disease emergencies.
- 1 November 2006
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 12 (11) , 1631-1637
Open AccessProphylaxis and Treatment of Pregnant Women for Emerging Infections and Bioterrorism Emergencies
Emerging infectious disease outbreaks and bioterrorism attacks warrant urgent public health and medical responses. Response plans for these events may include use of medications and vaccines for which the effects on pregnant women and fetuses are unknown. Healthcare providers must be able to discuss the benefits and risks of these interventions with their pregnant patients. Recent experiences with outbreaks of severe acute respiratory syndrome, monkeypox, and anthrax, as well as response planning for bioterrorism and pandemic influenza, illustrate the challenges of making recommendations about treatment and prophylaxis for pregnant women. Understanding the physiology of pregnancy, the factors that influence the teratogenic potential of medications and vaccines, and the infection control measures that may stop an outbreak will aid planners in making recommendations for care of pregnant women during large-scale infectious disease emergencies.